This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kaptein, E. M. Articles by Akmal, M. Search for Related Content PubMed PubMed Citation Articles by Kaptein, E. M. Articles by Akmal, M.

Radioiodine Dosimetry in Patients with End-Stage Renal Disease Receiving Continuous Ambulatory Peritoneal Dialysis Therapy¹

Departments of Medicine (E.M.K., M.G., M.A.) and Nuclear Medicine (H.L., M.E.S.), University of Southern California, Los Angeles, California 90033

Address all correspondence and requests for reprints to: Elaine M. Kaptein, M.D., University of Southern California, Room 4250 GNH, 1200 North State Street, Los Angeles, California 90033.

In patients with end-stage renal disease (ESRD), Na¹³¹I dosages for thyroid cancer may have to be reduced to avoid excess radiation doses to red marrow, because radioiodine is primarily excreted by kidneys. In ESRD patients receiving continuous ambulatory peritoneal dialysis (CAPD) therapy (three to five 2-L exchanges daily) creatinine clearance rates are very low (mean, 7 mL/min), and radioiodine clearance rates may be proportionately reduced. Thus, radioiodine kinetic studies were performed in two hypothyroid CAPD patients with thyroid cancer, in eight euthyroid CAPD patients, and in eight thyroid cancer patients with normal renal function. All received Na¹³¹I or Na¹²³I orally, with serial blood, urine, and/or dialysate sampling for 24–70 h. Dosimetry calculations were performed using the MIRDOSE3 computer program.

In CAPD patients, serum radioiodine half-times were 5 times longer, and radioiodine clearance rates by urine plus dialysate were 20% of those in patients with normal renal function. Na¹³¹I dosages for the two CAPD patients with thyroid cancer were reduced from 150 mCi [5.6 gigabecquerels (GBq)] to 26.6 mCi (0.98 GBq) and 29.9 mCi (1.11 GBq), respectively, resulting in radiation doses to red marrow and total body comparable to those in patients with normal renal function who received a mean of 148 mCi (5.5 GBq) Na¹³¹I. Thus, in patients receiving continuous ambulatory peritoneal dialysis therapy, 5-fold reductions in radioiodine clearance rates require 5-fold decreases in Na¹³¹I dosages to avoid excessive radiation doses to total body and red marrow.

This article has been cited by other articles:

				N. Magne, J. Magne, J. Bracco, and F. Bussiere Disposition of Radioiodine 131I Therapy for Thyroid Carcinoma in a Patient with Severely Impaired Renal Function on Chronic Dialysis: a Case Report Jpn. J. Clin. Oncol., June 1, 2002; 32(6): 202 - 205. [Abstract] [Full Text] [PDF]